• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019 年克罗地亚细菌对抗菌药物耐药性的负担:国家级系统分析。

The burden of bacterial antimicrobial resistance in Croatia in 2019: a country-level systematic analysis.

机构信息

Tomislav Meštrović, Department of Nursing, University Centre Varaždin, University North, Ul. 104. brigade 3, 42 000 Varaždin, Croatia,

出版信息

Croat Med J. 2023 Aug 31;64(4):272-283. doi: 10.3325/cmj.2023.64.272.

DOI:10.3325/cmj.2023.64.272
PMID:37654039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509683/
Abstract

AIM

To deliver the most wide-ranging set of antimicrobial resistance (AMR) burden estimates for Croatia to date.

METHODS

A complex modeling approach with five broad modeling components was used to estimate the disease burden for 12 main infectious syndromes and one residual group, 23 pathogenic bacteria, and 88 bug-drug combinations. This was represented by two relevant counterfactual scenarios: deaths/disability-adjusted life years (DALYs) that are attributable to AMR considering a situation where drug-resistant infections are substituted with sensitive ones, and deaths/DALYs associated with AMR considering a scenario where people with drug-resistant infections would instead present without any infection. The 95% uncertainty intervals (UI) were based on 1000 posterior draws in each modeling step, reported at the 2.5% and 97.5% of the draws' distribution, while out-of-sample predictive validation was pursued for all the models.

RESULTS

The total burden associated with AMR in Croatia was 2546 (95% UI 1558-3803) deaths and 46958 (28,033-71,628) DALYs, while the attributable burden was 614 (365-943) deaths and 11321 (6,544-17,809) DALYs. The highest number of deaths was established for bloodstream infections, followed by peritoneal and intra-abdominal infections and infections of the urinary tract. Five leading pathogenic bacterial agents were responsible for 1808 deaths associated with resistance: Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa (ordered by the number of deaths). Trimethoprim/sulfamethoxazole-resistant E coli and methicillin-resistant S. aureus were dominant pathogen-drug combinations in regard to mortality associated with and attributable to AMR, respectively.

CONCLUSION

We showed that AMR represented a substantial public health concern in Croatia, which reflects global trends; hence, our detailed country-level findings may fast-track the implementation of multipronged strategies tailored in accordance with leading pathogens and pathogen-drug combinations.

摘要

目的

提供迄今为止克罗地亚关于抗菌药物耐药性(AMR)负担的最全面估计。

方法

采用包含五个广泛建模组成部分的复杂建模方法,估计 12 种主要传染病综合征和一个剩余组、23 种病原体和 88 种细菌-药物组合的疾病负担。这通过两个相关的反事实情景来表示:考虑到耐药感染被敏感感染替代的情况下,归因于 AMR 的死亡/残疾调整生命年(DALY),以及考虑到具有耐药感染的人反而没有任何感染的情况下,与 AMR 相关的死亡/DALY。95%的不确定性区间(UI)基于每个建模步骤中的 1000 个后验抽取,在抽取分布的第 2.5%和第 97.5%处报告,同时对所有模型进行了样本外预测验证。

结果

克罗地亚与 AMR 相关的总负担为 2546 例死亡(95%UI 1558-3803)和 46958 个 DALY(28033-71628),而归因于 AMR 的负担为 614 例死亡(365-943)和 11321 个 DALY(6544-17809)。导致死亡人数最多的是血流感染,其次是腹膜和腹腔内感染以及尿路感染。五种主要病原体负责与耐药相关的 1808 例死亡:大肠杆菌、金黄色葡萄球菌、鲍曼不动杆菌、肺炎克雷伯菌和铜绿假单胞菌(按死亡人数排序)。甲氧苄啶/磺胺甲恶唑耐药大肠杆菌和耐甲氧西林金黄色葡萄球菌分别是与 AMR 相关和归因于 AMR 的死亡率方面的主要病原体-药物组合。

结论

我们表明,AMR 在克罗地亚是一个重大的公共卫生问题,反映了全球趋势;因此,我们详细的国家级发现可能会加快实施根据主要病原体和病原体-药物组合量身定制的多管齐下的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/834cb6f29e26/CroatMedJ_64_0272-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/9f6729ada6ad/CroatMedJ_64_0272-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/14b29c45b884/CroatMedJ_64_0272-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/c3896a3c1041/CroatMedJ_64_0272-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/834cb6f29e26/CroatMedJ_64_0272-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/9f6729ada6ad/CroatMedJ_64_0272-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/14b29c45b884/CroatMedJ_64_0272-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/c3896a3c1041/CroatMedJ_64_0272-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/471b/10509683/834cb6f29e26/CroatMedJ_64_0272-F4.jpg

相似文献

1
The burden of bacterial antimicrobial resistance in Croatia in 2019: a country-level systematic analysis.2019 年克罗地亚细菌对抗菌药物耐药性的负担:国家级系统分析。
Croat Med J. 2023 Aug 31;64(4):272-283. doi: 10.3325/cmj.2023.64.272.
2
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis.2019 年世卫组织欧洲区域细菌对抗菌药物耐药性的负担:跨国系统分析。
Lancet Public Health. 2022 Nov;7(11):e897-e913. doi: 10.1016/S2468-2667(22)00225-0. Epub 2022 Oct 14.
3
The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis.2019 年世卫组织非洲区域细菌对抗菌药物耐药性的负担:跨国系统分析。
Lancet Glob Health. 2024 Feb;12(2):e201-e216. doi: 10.1016/S2214-109X(23)00539-9. Epub 2023 Dec 19.
4
The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis.2019年美洲地区抗菌药物耐药性负担:一项跨国系统分析。
Lancet Reg Health Am. 2023 Aug 8;25:100561. doi: 10.1016/j.lana.2023.100561. eCollection 2023 Sep.
5
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
6
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.全球细菌对抗菌药物耐药性的负担 1990-2021:一项系统分析及对 2050 年的预测。
Lancet. 2024 Sep 28;404(10459):1199-1226. doi: 10.1016/S0140-6736(24)01867-1. Epub 2024 Sep 16.
7
Estimates of antibiotic resistance in Italy and Western Europe in 2019: a MICROBE-based comparative analysis.2019 年意大利和西欧的抗生素耐药性估计:基于微生物的比较分析。
Epidemiol Prev. 2024 Jan-Feb;48(1):48-59. doi: 10.19191/EP24.1.A648.020.
8
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.2019 年与 33 种细菌病原体相关的全球死亡率:2019 年全球疾病负担研究的系统分析。
Lancet. 2022 Dec 17;400(10369):2221-2248. doi: 10.1016/S0140-6736(22)02185-7. Epub 2022 Nov 21.
9
Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: A population-level study, Japan, 2015-2018.由抗菌药物耐药菌引起的血流感染的疾病负担:2015-2018 年日本的一项基于人群的研究。
Int J Infect Dis. 2021 Jul;108:119-124. doi: 10.1016/j.ijid.2021.05.018. Epub 2021 May 13.
10
Bacterial Epidemiology and Antimicrobial Resistance Profiles in Children Reported by the ISPED Program in China, 2016 to 2020.中国 ISPED 项目报告的 2016 至 2020 年儿童细菌流行病学和抗菌药物耐药性特征。
Microbiol Spectr. 2021 Dec 22;9(3):e0028321. doi: 10.1128/Spectrum.00283-21. Epub 2021 Nov 3.

引用本文的文献

1
Antimicrobial resistance burden landscape in Germany in 2019: a comparative country-level estimation.2019年德国抗菌药物耐药负担概况:国家层面的比较评估
JAC Antimicrob Resist. 2025 Aug 14;7(4):dlaf142. doi: 10.1093/jacamr/dlaf142. eCollection 2025 Aug.
2
Clovibactin and Staphylococcus aureus: a new weapon against resistant strains.克洛维菌素与金黄色葡萄球菌:对抗耐药菌株的新武器。
GMS Hyg Infect Control. 2024 Oct 23;19:Doc46. doi: 10.3205/dgkh000501. eCollection 2024.
3
In vitro antimicrobial and antioxidant activities of bioactive compounds extracted from Streptomyces africanus strain E2 isolated from Moroccan soil.

本文引用的文献

1
Antibiotic prophylaxis prior to transrectal prostate biopsy in Croatia: A national survey.抗生素预防在克罗地亚经直肠前列腺活检前:全国性调查。
Urologia. 2023 May;90(2):415-418. doi: 10.1177/03915603221143419. Epub 2022 Dec 16.
2
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis.2019 年世卫组织欧洲区域细菌对抗菌药物耐药性的负担:跨国系统分析。
Lancet Public Health. 2022 Nov;7(11):e897-e913. doi: 10.1016/S2468-2667(22)00225-0. Epub 2022 Oct 14.
3
Increasing trend in enterococcal bacteraemia and vancomycin resistance in a tertiary care hospital in Croatia, 2017-2021.
从摩洛哥土壤中分离出的非洲链霉菌 E2 菌株中提取的生物活性化合物的体外抗菌和抗氧化活性。
Sci Rep. 2024 Nov 9;14(1):27372. doi: 10.1038/s41598-024-77729-4.
4
Exploring the antimicrobial and antioxidant properties of strain E25-2 isolated from Moroccan forest soil.探索从摩洛哥森林土壤中分离出的E25-2菌株的抗菌和抗氧化特性。
Front Microbiol. 2024 Jul 22;15:1429035. doi: 10.3389/fmicb.2024.1429035. eCollection 2024.
2017 - 2021年克罗地亚一家三级护理医院肠球菌血症及万古霉素耐药性的上升趋势
Infect Dis (Lond). 2023 Jan;55(1):9-16. doi: 10.1080/23744235.2022.2131901. Epub 2022 Oct 14.
4
Global burden of antimicrobial resistance: essential pieces of a global puzzle - Authors' reply.抗菌药物耐药性的全球负担:全球难题的关键部分——作者回复
Lancet. 2022 Jun 25;399(10344):2349-2350. doi: 10.1016/S0140-6736(22)00947-3.
5
Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates among Croatian adults during a fifteen-year period (2005-2019).15 年间(2005-2019 年)克罗地亚成人侵袭性肺炎链球菌分离株的血清型分布和抗生素耐药性。
Croat Med J. 2022 Apr 30;63(2):156-165. doi: 10.3325/cmj.2022.63.156.
6
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
7
Diffusion of OXA-48 carbapenemase among urinary isolates of Klebsiella pneumoniae in non-hospitalized elderly patients.OXA-48 碳青霉烯酶在非住院老年患者中产 K. pneumoniae 的尿液分离株中的扩散。
BMC Microbiol. 2022 Jan 19;22(1):30. doi: 10.1186/s12866-022-02443-y.
8
Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome.抗菌药物耐药性:流行情况、经济负担、耐药机制和克服策略。
Eur J Pharm Sci. 2022 Mar 1;170:106103. doi: 10.1016/j.ejps.2021.106103. Epub 2021 Dec 20.
9
Antimicrobial resistance in as an independent risk factor for bacteraemia-related mortality.作为菌血症相关死亡率的独立危险因素的抗菌药物耐药性。 (你提供的原文似乎不太完整,感觉句子不太通顺,正常完整准确的句子可能会更有助于准确理解和翻译。)
Hong Kong Med J. 2021 Oct;27(5):385. doi: 10.12809/hkmj219773.
10
Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014-2018: Findings and Implications from ESAC-Net and WHO Europe.2014 - 2018年欧洲区域抗菌药物消费变化:ESAC - Net和世界卫生组织欧洲区域办事处的调查结果及影响
Front Pharmacol. 2021 Jun 17;12:639207. doi: 10.3389/fphar.2021.639207. eCollection 2021.